Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

LSPN Connect: CRISPR technologies
Biotech
In an LSPN Connect session, Millipore’s senior corporate patent counsel, Ben Sodey, and head of legal and IP at Arbor, Kelly Morgan, shared their insights on the latest developments in this area of gene editing technology.   21 August 2020
Sandoz gains backing for Enbrel patent term review
Pharma
Sandoz has gathered support for its request for an en banc rehearing of a ruling that blocks it from selling a version of  biologic Enbrel until 2029.   20 August 2020
Novartis secures victory as MS drug patent is upheld
Pharma
In a win for Novartis Pharmaceuticals, the US District Court for the district of Delaware has upheld the patent on its top-selling multiple sclerosis drug Gilenya.   18 August 2020
Pharma
Martin Shkreli conspired to illegally increase the price of a life-saving drug during phone calls he made from prison, according to the US Federal Trade Commission.   14 August 2020
Pharma
Bayer has settled a patent infringement suit with generics manufacturer Apotex, after claiming that its version of a cancer treatment infringed two patents.   13 August 2020
Pharma
US biotechnology company Novavax has signed a deal with Takeda Pharmaceuticals to develop, manufacture and market a COVID-19 vaccine in Japan, it was announced on Friday, August 7.   10 August 2020
Pharma
In a victory for Teva Pharmaceuticals, the US Court of Appeals for the Federal Circuit dismissed IBSA Institut Biochimique’s appeal against a ruling that held parts of its patent invalid.   10 August 2020
Pharma
Antibody patenting can be a minefield for IP practitioners if they lack the most up-to-date knowledge about the best way to approach a patent application.   6 August 2020
Americas
The US Court of Appeals for the Federal Circuit will not revisit its ruling that saved the patent eligibility of two DNA test patents owned by biotechnology company Illumina, after the court rejected an en banc request from a subsidiary of Roche.   6 August 2020
Genetics
The US Court of Appeals for the Federal Circuit has partially lifted an injunction on 10X Genomics, but the biotech company must still pay almost $24 million for infringing a Bio-Rad patent.   4 August 2020

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.